ADAR1 Capital Management’s Viridian Therapeutics VRDN Stock Holding History

ADAR1 Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-304,422	Closed	-$5.95M	–	345
2026 Q1	$5.95M	Buy	304,422 +227,224	+294%	+$6.75M	0.35%	64
2025 Q4	$2.4M	Sell	77,198 -24,506	-24%	-$672K	0.18%	90
2025 Q3	$2.19M	Sell	101,704 -68,894	-40%	-$1.24M	0.21%	76
2025 Q2	$2.38M	Buy	170,598 +91,598	+116%	+$1.24M	0.37%	50
2025 Q1	$1.06M	Buy	79,000 +53,000	+204%	+$903K	0.2%	78
2024 Q4	$498K	Buy	26,000 +16,794	+182%	+$365K	0.1%	110
2024 Q3	$209K	Buy	9,206 +1,206	+15%	+$19.7K	0.03%	161
2024 Q2	$104K	Buy	8,000 +5,450	+214%	+$75.4K	0.02%	164
2024 Q1	$44.6K	Buy	+2,550	New	+$49.4K	0.01%	187

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ADAR1 Capital Management's VRDN Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 304,422 shares — an estimated $5.95M sold.

ADAR1 Capital Management first reported a position in VRDN in Q1 2024 and held it in 9 quarters. The position peaked at $5.95M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

ADAR1 Capital Management reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
ADAR1 Capital Management sold 304,422 Viridian Therapeutics shares in Q2 2026, an estimated $5.95M.
ADAR1 Capital Management first reported a position in Viridian Therapeutics in Q1 2024 and held it in 9 quarters.
ADAR1 Capital Management's Viridian Therapeutics position peaked at $5.95M in Q1 2026.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.